BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Top 20: A sustained growth

02 August 2014 | Features | By BioSpectrum Bureau

Top 20: A sustained growth



top-20-logoHeadquartered in Hyderabad, GVK Biosciences is, today, one of the leading Contract Research Organizations (CROs) in Asia. It is estimated to have recorded Rs 599 crore in sales from its CRO business in 2013-14, registering over 37 percent growth. It is engaged in services across the R&D sphere with exclusive strengths and proprietary platforms in informatics. Its proprietary databases include SAR databases (GOSTAR), Biomarker database (GOBIOM), and other public databases. GOSTAR is a manually curated database and has been developed over the span of a decade by a team comprising of more than 200 scientists. The database and application are being used globally by pharmaceutical and biotechnology companies as well as academia and have been cited in numerous publications. GVK BIO recently licensed its popular SAR, PK and Toxicity Database (GOSTAR) to the US Food and Drug Administration (USFDA).

Other strong areas are its medicinal chemistry services and biology sector, where it provides target identification and HTS, ADME, and PK services. It also offers services involving synthesis of building blocks, advanced intermediates, and NCEs and Custom Chemical Synthesis and Manufacturing of Intermediates and APIs.

GVK BIO inked a collaboration agreement with US-based Endo Pharmaceuticals focused on discovering novel small molecules targeting an exciting protein. Under this agreement, GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product arising out of this collaboration. This collaboration arose out of a newly launched concept at GVK BIO named Early Discovery Assets (EDA). It also tied up with Onconova Therapeutics, a US-based biopharmaceutical company primarily focused on discovery and development of novel small molecules for Oncology. This joint partnership is to develop new drugs for Cancer. The joint partnership will be based in the US and will align research priorities and technological expertise from both companies to facilitate moving certain Onconova oncology assets from early discovery to clinical development stage.

GVK Bio recently acquired a privately held US-based, pre-clinical CRO specializing in high-value biologics services, Aragen Bioscience This deal will help GVK expand its service offerings to a broader base of organizations and gives GVK BIO expertise in biologics services and a significant US presence.